Articles: function.
-
Pulmonary Vascular Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: This patient diagnosed in 2005 with Idiopathic Pulmonary Arterial Hypertension was successfully treated with an ERA for 6 years. In October 2011, functional capacity decreased to IV and the patient was started on IV treprostinil by patient's choice. We achieved a dose of 50 ng-kg-min and patient returned to functional class II. Over time the dose was decreased to 34 ng-kg-min due to intolerable side effects resulting in functional III symptoms and worsening hemodynamics. The patient was given the option to transition to IV epoprostenol which we did on August 7, 2013. ⋯ The following authors have nothing to disclose: Carolyn Pugliese, Raylene Matlock, Ross Davies, Lisa Mielniczuk, George Chandy, Duncan Stewart, Vladimir Contreras-DominguezNo Product/Research Disclosure Information.
-
ILD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: This prospective study assessed the effect of inhaled N-acetylcysteine (NAC) monotherapy on lung function and redox balance in patients with idiopathic pulmonary fibrosis (IPF). ⋯ The following authors have nothing to disclose: Sakae Homma, Yoko Muramatsu, Keishi Sugino, Susumu Sakamoto, Junko Tatebe, Toshisuke MoritaNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Cardiogenic pulmonary edema occurring unilaterally is rare and presents diagnostic difficulties. ⋯ UCPE is an uncommon presentation; it should be considered in patients with unilateral pulmonary infiltrates and severely impaired left ventricular function or mitral valve diseases to avoid delay in diagnosis and appropriate treatment.Reference #1: Attias D, Mansencal N. Prevalence, characteristics, and outcomes of patients presenting with cardiogenic unilateral pulmonary edema. Circulation. 2010;122:1109-1115.Reference #2: Nitzan O, Saliba WR, Goldstein LH. Unilateral pulmonary edema: a rare presentation of congestive heart failure. Am J Med Sci. 2004; 327: 362-364Reference #3: Choi HS, Choi H, Han S, et al. Pulmonary edema during pregnancy: unilateral presentation is not rare. Circ J 2002;66:623-6DISCLOSURE: The following authors have nothing to disclose: Jessica Quah, Tan Keng LeongNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The current GOLD strategy recommends combining two long-acting bronchodilators for the maintenance treatment of patients with moderate-to-severe COPD. The SHINE study evaluated the effect of QVA149, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium (NVA237), compared with glycopyrronium, indacaterol, tiotropium monotherapies and placebo. ⋯ Kenneth Chapman: Consultant fee, speaker bureau, advisory committee, etc.: "KRC holds the GSK-CIHR Research Chair in Respiratory Healthcare Delivery at the University Health Network, has served as a consultant to CSL Behring, GlaxoSmithKline, Novartis, Nycomed (Takeda), and Talecris (Grifols), and has received payment for lectures or service on speakers bureaus from Boehringer-Ingelheim, GlaxoSmithKline, Grifols, Nycomed (Takeda), Family Physicians Airways Group of Canada, Canadian Network for Respiratory Care, and Talecris. " Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Nicola Gallagher: Employee: Novartis employee Huilin Hu: Employee: Novartis employee Donald Banerji: Employee: Novartis employeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The cryptogenic organizing pneumonia (COP) is a disease characterized by impairment of alveolar ducts and terminal bronchioles with inflammation. It was previously known as bronchiolitis obliterans organizing pneumonia (BOOP). It affects men and women with the same incidence and may be secondary to infections, drugs or be a primary manifestation. This case report presents a patient with COP whose approach dispensed, in accordance with the patient, lung biopsy for diagnosis. Only clinical data,laboratorial and image exams were used to define the conduct. ⋯ The patient improved dramatically after introduction of corticosteroid therapy, which has been decreasing gradually in posology. This case expresses an opportunity for choice by the patient, along with the physician and scientific evidence, to a personal approach for this disease.Reference #1: Vasu TS, Cavallazzi R, Hirani A, Sharma D, Weibel SB, Kane GC. Clinical and radiologic distinctions between secondary bronchiolitis obliterans organizing pneumonia and cryptogenic organizing pneumonia. Respir Care. 2009.Reference #2: Oymak FS, Demirbas HM, Mavili E, et al. Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration. 2005;723:254-262Reference #3: Sveinsson OA, Isaksson HJ, Sigvaldason A, Yngvason F, Aspelund T, Gudmundsson G. Clinical features in secondary and cryptogenic organising pneumonia. Int J Tuberc Lung Dis. 2009DISCLOSURE: The following authors have nothing to disclose: Gilmar Zonzin, Christian Boechat, Gabriela de Souza, Silvio Guerra, Priscila das Virgens, Jamile Abdalla, Vinícius AgostinhoNo Product/Research Disclosure Information.